The company has begun the shipment of anti-cholesterol drugs, atorvastatin calcium oral tablets, which will be produced at its Mohali SEZ plant in Punjab, the Business Standard reported.
The cholesterol lowering tablets meant for the US market will not be produced at the three units banned by the FDA, the company said.
The first consignment of atorvastatin tablets has been dispatched to the US market in March 2012, the company said.
Ranbaxy CEO and managing director Arun Sawhney said: "The resumption of supplies from India into the US market is a significant milestone for Ranbaxy. This is a testimony to our commitment to provide quality affordable medicines to the US healthcare system."